On Thursday, MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) announced the formulation of Ketamir-2 as a topical treatment for localized neuropathic and inflammatory pain. The advancement expands the ...
TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of ...
April 10 (Reuters) - Endo Pharmaceuticals Holdings Inc. said it is evaluating a notice from Anesiva Inc. on a New Drug Application filing of the latter's pain formulation Zingo. Endo believes that ...
Channel Therapeutics announced successful pre-clinical results for its non-opioid pain treatment formulations, outperforming bupivacaine in efficacy and duration. Channel Therapeutics Corporation has ...
Positive feedback from FDA suggests an indication from perioperative pain to all mild-to-moderate acute pain, significantly expanding clinical and commercial potential IND-enabling studies currently ...
The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne (JAN), the visionary biotech company dedicated to discovering ...
Algia Pharma, LLC ("Algia") today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak(R) toward a Phase 2 clinical trial upon completion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results